Capecitabine in combination with mitomycin C in patients with gastrointestinal cancer: Results of an extended multicentre phase-I trial

British Journal of Cancer

Volumn 91, Issue 5, 2004, Pages 834-838

  Hofheinz, R D ^a   Hartmann, J T ^b   Willer, A ^a   Oechsle, K ^b   Hartung, G ^c   Gnad, U ^a   Saussele, S ^a   Kreil, S ^a   Bokemeyer, C ^b   Hehlmann, R ^a   Hochhaus, A ^a  

^a MEDICAL FACULTY MANNHEIM HEIDELBERG UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^c UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

Capecitabine; Gastrointestinal cancer; Mitomycin C

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE; CREATININE; FLUOROURACIL; IRINOTECAN; MITOMYCIN C; OXALIPLATIN;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COLORECTAL CANCER; CREATININE BLOOD LEVEL; DIARRHEA; DIGESTIVE SYSTEM CANCER; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; ESOPHAGUS CANCER; FEMALE; HAND FOOT SYNDROME; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAUSEA; NEPHROTOXICITY; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; STOMACH CANCER; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GASTROINTESTINAL NEOPLASMS; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MITOMYCIN; TREATMENT OUTCOME;

EID: 4644305518     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6602025     Document Type: Article

References (27)

1. Borner MM, Dietrich D, Stupp R, Morant R, Honegger H, Wernli M, Herrmann R, Pestalozzi BC, Saletti P, Hanselmann S, Müller S, Brauchli P, Castiglione-Gertsch M, Goldhirsch A, Roth AD (2002) Phase II study of capecitabine and oxaliplatin in first- and second-line treatment of advanced or metastatic colorectal cancer. J Clin Oncol 20: 1759-1766
2. Cassidy J, Twelves C, van Cutsem E, Hoff P, Bajetta E, Boyer M, Bugat R, Burger U, Garin A, Graeven U, McKendrick J, Maroun J, Marshall J, Osterwalder B, Pérez-Manga G, Rosso R, Rougier P, Schilsky RL (2002) First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol 13: 566-575
3. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti A (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18: 2938-2947
4. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L, Rougier P (2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355: 1041-1047
5. Harba A, Jordan K, Kegel T, Behrens R, Grothey A, Schmoll HJ (2003) Capecitabine/mitomycin C as salvage therapy in oxaliplatin and CPT11 refractory advanced colorectal carcinoma (ACRC). Proc Am Soc Clin Oncol 22: 1335 (abstract)
6. Hartmann JT, Oechsle K, Quietzsch D, Wein A, Hofheinz RD, Honecker F, Nehls O, Kohne CH, Kafer G, Kanz L, Bokemeyer C (2003) Protracted infusional 5-fluorouracil plus high-dose folinic acid combined with bolus mitomycin C in patients with gastrointestinal cancer: a phase I/II dose escalation study. Br J Cancer 89: 2051-2056
7. Hartung G, Hofheinz R, Buchheidt D, Rost A, Brecht A, Forche K, Schröder M, Wojatschek C, Fritze D, Hehlmann R, Queisser W (2000) Combination of bolus 5-fluorouracil, folinic acid and mitomycin C in advanced gastric cancer: results of a phase II trial. Onkologie 23: 444-447
8. Hofheinz R, Hartung G, Samel S Hochhaus A, Pichlmeier U, Post S, Hehlmann R, Queisser W (2002) High-dose 5-fluorouracil/folinic acid in combination with three-weekly mitomycin C in the treatment of advanced gastric cancer. A phase-II study. Onkologie 25: 255-260
9. Hofheinz RD, Willer A, Weisser A, Gnad U, Saussele S, Kreil S, Hartmann JT, Hehlmann R, Hochhaus A (2004) Pegylated liposomal doxorubicin in combination with mitomycin C, infusional 5-fluorouracil and sodium folinic acid. A phase-I-study in patients with upper gastrointestinal cancer. Br J Cancer 90: 1893-1897
10. Kaplan EL, Maier P (1958) Non-parametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481
11. Kornek GV, Schuell B, Laengle F, Gruenberger T, Penz M, Karall K, Depisch D, Lang F, Scheithauer W (2004) Mitomycin C in combination with capecitabine or biweekly high-dose gemcitabine in patients with advanced biliary tract cancer: a randomised phase II trial. Ann Oncol 15: 478-483
12. Maisey N, Chau I, Cunningham D, Norman A, Seymour M, Hickish T, Iveson T, ÓBrien M, Tebbutt N, Harrington A, Hill M (2002) Multicenter randomized phase III trial comparing protracted venous infusion (PVI) fluorouracil (5-FU) with PVI 5-FU plus mitomycin in inoperable pancreatic cancer. J Clin Oncol 20: 3130-3136
13. O'Shaughnessy J, Miles D, Vukelja S, Moiseyenko V, Ayoub JP, Cervantes G, Fumoleau P, Jones S, Lui WY, Mauriac L, Twelves C, Van Hazel G, Verma S, Leonard R (2002) Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 20: 2812-2823
14. Rao S, Watkins D, Hill M, Price T, Norman A, Ward C, Oates J, Cunningham D (2003) Capecitabine and mitomycin C (MMC) shows promising activity as a 3rd line agent in patients with metastatic colorectal carcinoma (MCRC) resistant to 5FU and irinotecan. Proc Am Soc Clin Oncol 22: 1286 (abstract)
15. Ross P, Nicolson M, Cunningham D, Valle J, Seymour M, Harper P, Price T, Anderson H, Iveson T, Hickish T, Lofts F, Norman A (2002) Prospective randomized trial comparing mitomycin, cisplatin and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol 20: 1996-2004
16. Ross P, Norman A, Cunningham D, Webb A, Iveson T, Padhani A, Prendiville J, Watson M, Massey A, Popescu R, Oates J (1997) A prospective randomised trial of protracted venous infusion 5-fluorouracil with or without mitomycin C in advanced colorectal cancer. Ann Oncol 8: 995-1001
17. Rusello O, Romanini A, Civalleri D, Rosso R, Nicolin A, Sobrero A (1989) Time-dependent interactions between 5-fluorouracil and mitomycin C on a human colon cancer cell line, HCT-8 in vitro. Eur J Cancer Clin Oncol 25: 571-572
18. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL, Miller LL (2000) Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343: 905-914
19. Sartorelli AC, Boothe BA (1965) The synergistic anti-neoplastic activity of combinations of mitomycins with either 6-thioguanine or 5-fluorouracil. Cancer Res 25: 1393-1400
20. Sawada N, Ishikawa T, Fukase Y, Nishida M, Yoshikubo T, Ishitsuka H (1998) Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. Clin Cancer Res 4: 1013-1019
21. Scheithauer W, Schüll B, Ulrich-Pur H, Schmid K, Raderer M, Haider K, Kwasny W, Depisch D, Schneeweiss B, Lang F, Kornek GV (2003) Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial. Ann Oncol 14: 97-104
22. Schüller J, Cassidy J, Dumont E, Roos B, Durston S, Banken L, Utoh M, Mori K, Weidekamm E, Reigner B (2000) Preferential activation of capecitabine in tumor following oral administration in colorectal cancer patients. Cancer Chemother Pharmacol 45: 291-297
23. Tewes M, Schleucher N, Achterrath W, Wilke HJ, Frings S, Seeber S, Harstrick A, Rustum YM, Vanhoefer U (2003) Capecitabine and irinotecan as first-line chemotherapy in patients with metastatic colorectal cancer: results of an extended phase I study. Ann Oncol 14: 1442-1448
24. Twelves C, on behalf of the Xeloda Colorectal Cancer Group (2002) Capecitabine as first-line treatment in colorectal cancer pooled. Pooled data from two large, phase III trials. Eur J Cancer 38(Suppl 2): 15-20
25. Venturini M, Del Mastro L, Garrone O, Angiolini C, Merlano M, Bergaglio M, Tolino G, Lambiase A, Baldini A, Canavese G, Rosso R (2002) Phase I, dose-finding study of capecitabine in combination with docetaxel and epirubicin as first-line chemotherapy for advanced breast cancer. Ann Oncol 13: 546-552
26. Watkins D, Rao S, Cunningham D, Hill M, Price T, Norman A, Tebbutt N, Shellito P (2003) Capecitabine and mitomycin-C: an active low toxicity first line therapy in metastatic colorectal cancer (MCRC). Proc Am Soc Clin Oncol 22: 1109 (abstract)
27. Yamshita K, Tsunoda T, Urakami A, Iwamoto S, Kimoto M, Iki K, Hayashi J, Oka Y, Fujikura H, Ikeda M, Hirabayashi Y (2001) Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by mitomycin c (MMC) in human colorectal cancer (CC). Proc Am Soc Clin Oncol 20: 600 (abstract)